{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:35:56Z","timestamp":1781242556861,"version":"3.54.1"},"reference-count":28,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Central nervous system (CNS) metastasis is common in advanced melanoma patients. New treatment options have improved overall prognosis, but information is lacking for patients with CNS metastases. We investigated treatment patterns and survival outcomes in older melanoma patients with and without CNS metastases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis of SEER\u2010Medicare, a population\u2010based linked database, was undertaken in patients aged\u00a0&gt;\u00a065\u00a0years with advanced melanoma diagnosed from 2004 to 2011 and followed until 2013.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2522 patients were included. CNS metastases were present in 24.8% of patients at initial metastatic diagnosis; 16.5% developed CNS metastases during follow\u2010up. Chemotherapy was the most common treatment regardless of CNS metastases. Overall survival (OS) was better for patients without CNS metastases (median, 9.5\u00a0months; 95% confidence interval [CI], 8.8\u201010.2) vs patients with CNS metastases (3.63\u00a0months; 95% CI, 3.4\u20103.9). Among patients with CNS metastases, median OS for targeted therapy, immunotherapy, and chemotherapy was 6 (95% CI, 2.5\u20109.6), 5.5 (95% CI, 3.8\u20107.5), and 4.5 (95% CI, 3.8\u20105.4) months, respectively, vs 2.4 (95% CI, 2.1\u20102.7) and 2.1 (95% CI, 1.8\u20102.7) months for local radiotherapy and no treatment, respectively. Stereotactic radiosurgery demonstrated higher OS vs whole\u2010brain radiation therapy (median, 4.98 [95% CI, 3.5\u20107.5] vs 2.4 [95% CI, 2.1\u20102.7] months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with CNS metastases from melanoma remain a population with high unmet medical need despite recent advances in treatment. Systemic treatments (eg, BRAF\u2010targeted therapy and immunotherapy) and stereotactic radiosurgery demonstrated meaningful but modest improvements in OS. Further explorations of combinations of radiotherapy, BRAF\u2010targeted therapies, and immunotherapies are needed.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.3256","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T12:41:54Z","timestamp":1594816914000},"page":"6216-6224","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER\u2010Medicare analysis"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2469-468X","authenticated-orcid":false,"given":"Natalia","family":"Sadetsky","sequence":"first","affiliation":[{"name":"Real World Data Science \u2013 Product Development Genentech, Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Real World Data Science \u2013 Product Development Genentech, Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Wallick","sequence":"additional","affiliation":[{"name":"US Medical Affairs Genentech, Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward F.","family":"McKenna","sequence":"additional","affiliation":[{"name":"US Medical Affairs Genentech, Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[{"name":"Genesis Research LLC Hoboken NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn E.","family":"Colburn","sequence":"additional","affiliation":[{"name":"Product Development \u2013 Oncology Genentech, Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12538"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.04.032"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.140"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1206"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9507"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw417"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw641"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200208001-00008"},{"issue":"4","key":"e_1_2_10_17_1","first-page":"5","article-title":"Overview of the SEER\u2013medicare health outcomes survey linked dataset","volume":"29","author":"Ambs A","year":"2008","journal-title":"Health Care Financ Rev"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00256-0"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.08.007"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-9943-z"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.178"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30825-X"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.07.002"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70431-X"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.11.002"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.03.003"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.142"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj363"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.3256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.3256","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T14:48:53Z","timestamp":1728571733000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.3256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/cam4.3256"],"URL":"https:\/\/doi.org\/10.1002\/cam4.3256","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"2020-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}